The estimated Net Worth of Remi Corlin is at least 426 千$ dollars as of 8 August 2008. Remi Corlin owns over 18,500 units of Haemonetics stock worth over 426,296$ and over the last 19 years Remi sold HAE stock worth over 0$.
Remi has made over 2 trades of the Haemonetics stock since 2006, according to the Form 4 filled with the SEC. Most recently Remi exercised 18,500 units of HAE stock worth 559,810$ on 8 August 2008.
The largest trade Remi's ever made was exercising 18,500 units of Haemonetics stock on 8 August 2008 worth over 559,810$. On average, Remi trades about 5,250 units every 179 days since 2006. As of 8 August 2008 Remi still owns at least 5,884 units of Haemonetics stock.
You can see the complete history of Remi Corlin stock trades at the bottom of the page.
Remi's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.
Over the last 21 years, insiders at Haemonetics have traded over 82,114,016$ worth of Haemonetics stock and bought 334,931 units worth 14,646,550$ . The most active insiders traders include Paul Black、Robert E Abernathy、Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of 539,753$. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth 393,039$.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: